Zynerba Pharmaceuticals
0
0
+€0.00+0% 00:00 Today
Statistics
Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
About
Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically-produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Devon, Pennsylvania.
Show more...
CEO
Mr. Armando Anido MBA
Employees
28
Country
United States
ISIN
US98986X1090
Listings
0 Comments
Share your thoughts
FAQ
What is Zynerba Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Stuttgart exchange Zynerba Pharmaceuticals stocks are traded under the ticker 6ZY.STU.
How many employees does Zynerba Pharmaceuticals have?▼
As of July 17, 2026, the company has 28 employees.
In which sector is Zynerba Pharmaceuticals located?▼
Zynerba Pharmaceuticals operates in the Other sector.
When did Zynerba Pharmaceuticals complete a stock split?▼
Zynerba Pharmaceuticals has not had any recent stock splits.
Where is Zynerba Pharmaceuticals headquartered?▼
Zynerba Pharmaceuticals is headquartered in Devon, United States.